Azithromycin-induced severe cutaneous reactions occur rare. We report a case of azithromycin-induced generalized nonbullous form of fixed-drug eruption (FDE). A 19-year-old male consulted the dermatology department for multiple painful oval-shaped, sharply defined, and hyperpigmented patches on his chest, abdomen, and upper limbs after consuming oral azithromycin tablets for his sore throat. The generalized nonbullous form of FDE was diagnosed, and the offending drug was stopped immediately. He was treated with antihistamines and steroids, and recovered on follow-up. This FDE is reported due to the spareseness of documentation from South India and to improve the awareness among the prescribing physicians about this severe cutaneous reaction (FDE) for a commonly used drug. This case report gives insight to the clinicians and health-care workers on rare side effects caused by the commonly used antimicrobial agent, azithromycin.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642587 | PMC |
http://dx.doi.org/10.4103/jrpp.jrpp_55_22 | DOI Listing |
Aust J Gen Pract
December 2023
MBBS (Hons), MPhil, FACD, Consultant Dermatologist, Dermatology Department, Northern Hospital, Melbourne, Vic; Consultant Dermatologist, Preston Dermatology and Specialist Centre, Melbourne, Vic.
Background: Older patients with a red scaly eruption often present first to a primary care practitioner. A thorough clinical assessment can help delineate between common causes and assist the clinician with the next steps in management.
Objective: This article discusses the assessment of acute- to subacute-onset erythematous and scaly plaques that are present on multiple body sites in a patient aged >65 years.
J Res Pharm Pract
August 2023
Department of Pharmacology, Sri Venkateshwaraa Medical College Hospital and Research Institute, Puducherry, India.
Azithromycin-induced severe cutaneous reactions occur rare. We report a case of azithromycin-induced generalized nonbullous form of fixed-drug eruption (FDE). A 19-year-old male consulted the dermatology department for multiple painful oval-shaped, sharply defined, and hyperpigmented patches on his chest, abdomen, and upper limbs after consuming oral azithromycin tablets for his sore throat.
View Article and Find Full Text PDFFixed drug eruption is a cutaneous drug reaction which recurs at the same site when the individual is exposed to the causative drug, characterized by single or multiple round sharply demarcated erythematous-to-violaceous patches. Here, we report a patient with generalized non-bullous fixed drug eruption following mRNA-based Pfizer-BioNTech COVID-19 vaccine.
View Article and Find Full Text PDFAm J Case Rep
September 2021
Department of Internal Medicine, Roger William Medical Center, Providence, RI, USA.
BACKGROUND Bullous pemphigoid is a common pruritic skin lesion reported in elderly patients. It is caused by an immunologic reaction between autoantibodies and hemidesmosome proteins of epithelial cells. The disease is characterized by a symmetrical blister distribution on the body.
View Article and Find Full Text PDFEur J Dermatol
June 2021
Pathology department, Henri Mondor hospital, AP-HP, 94010 Créteil Cedex, France, Intensive care unit, Henri Mondor hospital, AP-HP, 94010 Créteil Cedex, France, Reference centre for toxic bullous diseases and severe cutaneous adverse reactions TOXIBUL, Créteil, France.
The clinical and pathological aspects of fixed drug eruption (FDE) have been described based on a few case series. To compare bullous FDE (BFDE) and non-bullous FDE (NBFDE) and to determine whether BFDE can be histologically distinguished from other dermatoses presenting with an apoptotic pan-epidermolysis. In this retrospective monocentre study (2005-2016), FDE was classified as BFDE or NBFDE and localized (one anatomical site) or generalized (≥ two sites; GBFDE).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!